Join us for a poster highlight of the top abstracts from the Pediatric Liver Disorders (PLD) SIG.&nbsp;<br />
&nbsp;

This session on alcohol-associated liver disease (ALD) provides a comprehensive overview from both patient and physician perspectives, emphasizing early detection, equitable access to treatment, and inclusive research practices. The session includes a patient sharing their experiences, highlighting the physical and emotional challenges of living with ALD and the importance of support systems. Physicians discuss early detection, detailing diagnostic tools and the benefits of early intervention. They also address how disparities influence access to liver transplantation and clinical trial opportunities, and propose strategies that center on equity. After the individual presentations, a panel of speakers answer questions from the audience and engage in a dialogue about the future directions in ALD detection, treatment, and research. 

Developed by the Patient Advisory Group, this session focuses on types of palliative care throughout various stages of liver disease, and how palliative care can be helpful for both patients with liver disease and their caregivers.

The central conflict in the conversation about liver transplants for patients with Alcohol-Associated Liver Disease (ALD) is the stark clash between medical ethics and moral judgment. Critics argue these patients are &quot;undeserving&quot; because their illness is perceived as &quot;self-inflicted,&quot; suggesting they shouldn&#39;t compete for scarce organs with &quot;blameless&quot; individuals. We will talk to these patients and see how they navigate these murky waters when confronted with these issues.<br />
<br />
<strong>Zoom:</strong><a href="https://us06web.zoom.us/j/81878086913?pwd=Sum5bOxh4xtwZQ5zwRUd8FZJbXqYX…;

Explore the metabolic connections between obesity, MASLD/MASH, and cardiometabolic diseases, and how incorporating obesity care in hepatology practice can improve multiple health outcomes. Join expert clinicians for an in-depth discussion on the vital role of hepatology in obesity care and the importance of collaborative care.<br />
<br />
Industry Supporter::&nbsp;Boehringer Ingelheim Pharmaceuticals, Inc.

Join us for a poster highlight of the top abstracts from the MASLD SIG.&nbsp;<br />
&nbsp;

Presenters in this symposium focus on the varied functions of liver endothelial cells (ECs). ECs are specialized cells increasingly recognized for their heterogeneity and their key role in liver diseases and carcinogenesis. Recent advances in the understanding of EC function were made possible with refined isolation techniques coupled with multiomics studies. Speakers review emerging literature that defines liver ECs beyond their role as vascular barriers to critical mediators in various biological processes under physiologic and pathologic conditions. 

This session will explore the clinical significance of comprehensive biomarker testing in chronic hepatitis B (CHB), focusing on how quantitative and qualitative HBsAg, HBeAg, and HBV DNA testing can help offer more personalized care to CHB patients by characterizing disease phases, supporting better-informed treatment decisions, and improving monitoring strategies.<br />
<br />
Industry Supporter:&nbsp;GSK

This engaging, interactive session kicks off with an advocate leader hosting "Excuses Bingo," challenging participants to recognize and move past the barriers that hold us back. From there, we hear from a passionate leader in advocacy who shares a message of hope and empowerment. Leading medical experts then offer insights on hope through science, discussing breakthroughs across a spectrum of liver diseases. Finally, a diverse panel explores the shared struggles and victories across liver diseases, emphasizing impact, progress, and the unifying hope that connects us all. No matter the diagnosis, we move forward together—passing the baton toward a healthier future.